Showing results (31-40 of 63) with videos related to
Sort By:
Pageof 7
Breast Cancer Research and Treatment|February 14, 2009
CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriersSarai Palanca Suela, Eva Esteban Cardeñosa, Eva Barragán González, et al.Cancers|February 14, 2020
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young WomenSara S Oltra, Juan Miguel Cejalvo, Eduardo Tormo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR studyChristophe Tournigand, Andres Cervantes, Arie Figer, et al.American Journal of Cancer Research|September 2, 2015
Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicineRosa Murria, Sarai Palanca, Inmaculada de Juan, et al.Familial Cancer|August 17, 2010
Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidenceEva Esteban Cardeñosa, Pascual Bolufer Gilabert, Inmaculada de Juan Jiménez, et al.Breast Cancer Research and Treatment|October 25, 2014
Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancersJon Zugazagoitia, Pedro Pérez-Segura, Arancha Manzano, et al.Breast Cancer Research and Treatment|October 17, 2013
MicroRNA signatures in hereditary breast cancerRosa Murria Estal, Sarai Palanca Suela, Inmaculada de Juan Jiménez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancerAimery de Gramont, Marc Buyse, Jose Cortinas Abrahantes, et al.Hereditary Cancer in Clinical Practice|January 25, 2019
Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS)Marta Ramírez-Calvo, Zaida García-Casado, Antonio Fernández-Serra, et al.European Urology Open Science|June 18, 2025
Corrigendum to "Prognostic Expression Signature of <i>RB1</i>, <i>PTEN</i>, and <i>TP53</i> Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors" [Eur. Urol. Open Sci. 70 (2024) 86-90]Marta Garcia de Herreros, Natalia Jiménez, Leonardo Rodríguez-Carunchio, et al.Pageof 7